VASCEPA Also Significantly Improved Multiple Lipid Parameters by Reducing VLDL-C, Non-HDL-C, APO B, and TC in Statin-Treated Patients as Compared to Placebo1

Median Percent Change in Other Lipid Biomarkers Compared to Placebo1

ANCHOR Efficacy other biomarkers
  • VASCEPA significantly reduced TG, VLDL-C, non-HDL-C, Apo B, TC, and HDL-C levels from baseline relative to placebo
  • The reduction in TG observed with VASCEPA was not associated with elevations in LDL-C relative to placebo



Reference: 1. Ballantyne CM, Bays HE, Kastelein JJ, et al. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984-992.